JSC „Grindeks” informs on negotiations with Byelorussian Pharmaceutical Company RUE “Borisov Medical Preparations Plant”

JSC „Grindeks” informs that  company carries on  negotiations with Byelorussian
Pharmaceutical Company RUE “Borisov Medical Preparations Plant” regarding
possible investment project and development of joint venture company. 

JSC „Grindeks” will approve its readiness to get engaged in the investment
project and development of joint venture company only after rigorous business
studies and data analyses is carried out. „Grindeks” informs, that project
costs and dates mentioned in the publication „Липман ставит условия Черепку” by
„Telegraf” (22 October, 2008) are estimated approximately and will be defined
more precisely during the project. 

About "Grindeks" 

JSC "Grindeks" is the leading pharmaceutical company in the Baltic States. Its
main fields of action are: research, development and manufacturing of brand
products, generics and active pharmaceutical ingredients. "Grindeks"
specializes in the heart and cardiovascular, CNS and anti-cancer medication
therapeutic groups. 

A range of "Grindeks" products covers a successful combination of original
products and generics, with the original products Mildronate® and Ftorafur® and
more than 100 forms of effective and safe generics included therein. 

"Grindeks" concern consists of four subsidiary companies in Latvia, Estonia and
Russia, as well representatives and representative offices in fourteen
countries. Products of the company are exported to more than 40 countries and
its export comprises more than 96% of the total turnover. The main markets are:
the Baltic States, Russia and other CIS countries, Japan, USA. "Grindeks"
shares are listed in the Official List of Riga Stock Exchange. 

Contacts:
Laila Kļaviņa
Head of the Communications Department
JSC Grindeks
Phones: +371 67083370, + 371 29256012
e-mail: laila.klavina@grindeks.lv